Search Videos and More
Video
Paolo Tarantino, MD discusses the DATO - Base study
Paolo Tarantino, MD, of Dana-Farber Cancer Institute, presented new findings from the DATO-Base study examining treatment with the ADC Dato-DXd for women with leptomeningeal disease. Breast cancer is the most common cancer linked to this rare but serious condition.
Video
Erica Mayer, MD discusses results from TBCRC 56 study
Erica Mayer, MD, of Dana-Farber Cancer Institute shared results from TBCRC 56, showing presurgical treatment with a PARP inhibitor + anti-PD1 combo in patients with gBRCAm early triple-negative breast cancer resulted in a pCR rate of 50%. Further ongoing correlative work may identify the best candidates for this non-chemo approach.
Video
Rachel Freedman, MD discusses phase 2 ATOP study
Dana-Farber Cancer Institute's Rachel Freedman, MD, presents results from the phase 2 ATOP study showing older patients with HER2+ breast cancer receiving adjuvant T-DM1 had a favorable 5-year survival with manageable toxicity. ATOP is the 1st adjuvant trial for older patients with HER2+ breast cancer in the United States.
Video
Stefania Morganti, MD discusses ctDNA study
Ultrasensitive detection of minimal residual disease using ctDNA can help predict the duration of response to HER2 targeted therapy in patients with metastatic breast cancer, according to a study presented by Stefani Morganti, MD, of Dana-Farber Cancer Institute.
Video
Ann Partridge, MD discusses YES study
Breast cancer survivors who used a novel mobile health intervention to self-manage post-treatment symptoms were able to improve their quality of life and reduce the burden of common symptoms, according to results of the YES study presented by Ann Partridge, MD, of Dana-Farber Cancer Institute.
News
Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.
News
Dana-Farber researchers present findings at 2025 San Antonio Breast Cancer Symposium
Physician scientists from Dana-Farber Cancer Institute will present more than 50 research studies at the 48th annual San Antonio Breast Cancer Symposium, December 9-12.
Document
Treatment Guideline: Inavolisib, Palbociclib, and Fulvestrant for Hormone Receptor-Positive/HER2-negative Metastatic Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held meetings to discuss recommendations regarding the use of inavolisib, palbociclib, and fulvestrant in patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
Symposium
San Antonio Breast Cancer Symposium 2025
Dana-Farber Cancer Institute Faculty highlights from the 2025 San Antonio Breast Cancer Symposium.
Symposium
ESMO Congress 2025
Review video summaries and research highlights from Dana-Farber Faculty, presented at ESMO Congress 2025.
Document
Treatment Guideline: Ovarian Function Suppression and Estradiol Monitoring in Early-Stage Estrogen Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of ovarian function suppression and estradiol monitoring in early-stage estrogen receptor positive breast cancer.
News
ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.